| Autor: |
Fernández, Sara, Solórzano, Jose L., Díaz, Eva, Menéndez, Victoria, Maestre, Lorena, Palacios, Sara, López, Mar, Colmenero, Argentina, Estévez, Mónica, Montalbán, Carlos, Martínez, Ángel, Roncador, Giovanna, García, Juan F. |
| Zdroj: |
Blood Advances; 20220101, Issue: Preprints |
| Abstrakt: |
Constitutive activation of the JAK/STAT pathway is a common phenomenon in classic Hodgkin lymphoma (cHL). The clinical potential of anti-JAK/STAT therapy is being explored in early-stage clinical trials. Notwithstanding, very little information is available about the complex biological consequences of this blockade. Here we investigated the effects of JAK/STAT pharmacological inhibition on cHL cell models using ruxolitinib, a JAK 1/2 inhibitor that induces apoptosis by concentration- and time-dependent mechanisms. An unbiased whole-transcriptome approach identified expression of the anti-GCSF receptor (CSF3R) as a potential surrogate biomarker of JAK/STAT overactivation. Additionally, longitudinal gene expression analyses provided further mechanistic information about pertinent biological pathways involved, including 37 gene pathways distributed in three main clusters: one was characterized by upregulation of the G2/M checkpoint and MHC-related clusters; two additional clusters showed a progressive down regulation of the tumor-promoting inflammation signatures: JAK/STAT and IL1/IL4/IL13/IL17. Together, our results confirm the therapeutic potential of JAK/STAT inhibitors in cHL, identify CSF3R as a new biomarker, and provide supporting genetic data and mechanistic understanding. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
